Health TrialsbyHealthPanel

Suhexiang Pill for Acute Ischemic Stroke: A Registry Study

ConditionIschemic Stroke
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorDongzhimen Hospital, Beijing

About this trial

The primary purpose of this study is to investigate the effectiveness and safety of the Suhexiang Pill for patients with acute ischemic stroke in real-world settings.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Acute ischemic stroke within 7 days of symptom onset.

Age ≥ 18

Patient who has received Suhexiang Pill treatment

Patient or legally authorized representative has signed informed consent.

Disqualifiers

Be allergic to Suhexiang Pill

Known to be pregnant or breastfeeding.

With conditions that render outcomes or follow-up unlikely to be assessed.

Trial population

Patients diagnosed with Acute ischemic stroke.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Suhexiang Pill

    Drug

    Suhexiang Pill is an approved traditional Chinese patent medicine.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Proportion of patients independent

Proportion of patients independent is defined as the modified Rankin Scale score of 0, 1, or 2.

Time frame
90 days

Secondary outcomes

1

National Institute of Health Stroke Scale

The National Institute of Health Stroke Scale (NIHSS) ranges from 0 to 42, with higher scores indicating more severe neurological deficits.

Time frame
The change from baseline to day 10 or discharge.
2

Glasgow Coma Scale

The Glasgow Coma Scale (GCS) is used to describe the extent of impaired consciousness in all types of acute medical and trauma patients, ranging from 0 to 15, with lower scores indicating more severe impaired consciousness.

Time frame
The change from baseline to day 10 or discharge.
3

Patient reported outcome

The patient reported outcome (PRO) scale of stroke consists of four dimensions including the influence on physical, emotional, and social functioning, as well as the overall satisfaction with treatment.

Time frame
At day 10 or discharge.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Dongzhimen Hospital, Beijing

Lead sponsor

Source ClinicalTrials.gov
Apply now